다약제 치료를 받는 조현병 환자에서 Aripiprazole Once-Monthly 투여의 임상적 부담
Clinical Burden of Aripiprazole Once-Monthly in Patients With Schizophrenia Receiving Antipsychotic Polypharmacy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives This study aimed to assess the clinical burden, a critical determinant of medication adherence in patients with schizophrenia, after the administration of Aripiprazole once-monthly (AOM). Methods This study was a retrospective, non-interventional, multicenter, naturalistic observational study conducted through the analysis of participants’ electronic medical records. Study participants were recruited from eight sites. Data were collected at baseline, defined as the time of AOM administration, and at 1, 3, 6, 9, and 12 months thereafter. The primary outcome measure was the change in the Clinical Global Impression-Clinical Benefit (CGI-CB) score over 12 months, and the secondary outcome measure was the change in the Clinical Global Impression-Improvement (CGI-I) score. Results The data of 139 participants were analyzed, revealing a statistically significant decrease of 26.8% in CGI-CB scores and 13.4% in CGI-I scores over 12 months. Upon comparison between adjacent visit intervals, significant reductions were observed for both measures between month 3 and month 6. Conclusions This study is the first multicenter investigation to simultaneously evaluate the clinical efficacy and tolerability of transitioning to AOM in the context of polypharmacy. The study suggested that AOM may contribute to reducing the clinical burden, thereby improving the quality of life for patients with schizophrenia.
Abstract
Objectives This study aimed to assess the clinical burden, a critical determinant of medication adherence in patients with schizophrenia, after the administration of Aripiprazole once-monthly (AOM). Methods This study was a retrospective, non-interventional, multicenter, naturalistic observational study conducted through the analysis of participants’ electronic medical records. Study participants were recruited from eight sites. Data were collected at baseline, defined as the time of AOM administration, and at 1, 3, 6, 9, and 12 months thereafter. The primary outcome measure was the change in the Clinical Global Impression-Clinical Benefit (CGI-CB) score over 12 months, and the secondary outcome measure was the change in the Clinical Global Impression-Improvement (CGI-I) score. Results The data of 139 participants were analyzed, revealing a statistically significant decrease of 26.8% in CGI-CB scores and 13.4% in CGI-I scores over 12 months. Upon comparison between adjacent visit intervals, significant reductions were observed for both measures between month 3 and month 6. Conclusions This study is the first multicenter investigation to simultaneously evaluate the clinical efficacy and tolerability of transitioning to AOM in the context of polypharmacy. The study suggested that AOM may contribute to reducing the clinical burden, thereby improving the quality of life for patients with schizophrenia.
참고문헌 (21)
- Pae CU, "Consideration of long-acting injectable antipsychotics for polypharmacy regimen in the treatment of schizophrenia : put it on the table or not?", Clin Psychopharmacol Neurosci, 19, pp.434~448 (2021)
- Yan T, "Medication adherence and discontinuation of aripiprazole once-monthly 400 mg(AOM 400)versus oral antipsychotics in patients with schizophrenia or bipolar I disorder : a real-world study using US claims data", Adv Ther, 35, pp.1612~1625 (2018)
- Schöttle D, "The use of long-acting aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany : a report on global assessment of functioning and the WHO wellbeing index", BMC Psychiatry, 20, pp.77~ (2020)
- Schöttle D, "Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole : a 6-month, reallife non-interventional study", BMC Psychiatry, 18, pp.365~ (2018)
- Schöttle D, "Real-world effectiveness of aripiprazole once-monthly REACT study : pooled analysis of two noninterventional studies", Eur Psychiatry, 65, pp.e42~ (2022)
- Schöttle D, "BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia(REACT study)", BMC Psychiatry, 23, pp.162~ (2023)
- Pae CU, "Effectiveness and tolerability of switching to aripiprazole once monthly from antipsychotic polypharmacy and", or other long acting injectable antipsychotics for patients with schizophrenia in routine practice : a retrospective, observation study, 2020, pp.18, 153~158
- Pae CU, "Clinical benefit and utility of switching to aripiprazole once monthly in patients with antipsychotic polypharmacy or long acting injectable antipsychotics for patients with schizophrenia in routine practice : a retrospective, observation study", Clin Psychopharmacol Neurosci, 19, pp.233~242 (2021)
- Kim SW, "Effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia", Clin Psychopharmacol Neurosci, 21, pp.57~67 (2023)
- Mustafa S, "Real-life assessment of aripiprazole monthly(Abilify Maintena)in schizophrenia : a Canadian naturalistic non-interventional prospective cohort study", BMC Psychiatry, 19, pp.114~ (2019)
- Guo J, "Influencing factors of medication adherence in schizophrenic patients : a meta-analysis", Schizophrenia(Heidelb), 9, pp.31~ (2023)
- Llorca PM, "Partial compliance in schizophrenia and the impact on patient outcomes", Psychiatry Res, 161, pp.235~247 (2008)
- Weiden PJ, "Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia", Psychiatr Serv, 55, pp.886~891 (2004)
- American Psychiatric Association. Diagnostic, "Diagnostic and statistical manual of mental disorders (DSM-5)" (2013), American Psychiatric Association
- Guy W, "ECDEU assessment manual for psychopharmacology", National Institute of Mental Health, ~ (1976)
- Kim Y, "Amisulpride switching in schizophrenic patients who showed suboptimal effect and", or tolerability to current antipsychotics in a naturalistic setting : an explorative study, 2016, pp.14, 371~377
- Ganesan S, "Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia", Curr Med Res Opin, 24, pp.21~32 (2008)
- Chue P, "A review of aripiprazole long-acting injection", Curr Med Res Opin, 32, pp.441~452 (2016)
- Peters-Strickland T, "Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics", CNS Spectr, 21, pp.460~465 (2016)
- Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
- Gupta S, "Deprescribing antipsychotics : a guide for clinicians", BJPsych Adv, 24, pp.295~302 (2018)